Jefferies lowered the firm’s price target on Align Technology (ALGN) to $260 from $285 and keeps a Buy rating on the shares. With “reasonable expectations” and valuation well below the historical average, any reacceleration will likely push Align’s multiple higher despite sluggish case starts and macro headwinds, the analyst tells investors in a note on the dental group.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGN:
- Align Technology names NFL quarterback Patrick Mahomes as brand ambassador
- Align Technology upgraded to Outperform from Market Perform at Leerink
- Align Technology price target raised to $206 from $200 at BofA
- GE Vernova initiated, Merck upgraded: Wall Street’s top analyst calls
- Align Technology initiated with an Outperform at Mizuho